Aarti Drugs Limited

Manufacturers of : Bulk Drugs & Chemicals

Corporate Office : Mahendra Industrial Estate,
Ground Floor, Plot No. 109-D, Road No. 29,
Sion (East), Mumbai - 400 022. (India)
Tel.: 022-2407 2249 / 2401 9025 (30 Lines)
Fax : 022-2407 3462 / 2407 0144
Email : finacc@aartidrugs.com
Website : www.aartidrugs.com

Ref. No: ADL/2-T/2012/18
Date: 9th July, 2012.

TO,
THE DEPARTMENT OF CORPORATE SERVICES
BOMBAY STOCK EXCHANGE LTD.
PHIROZE JEEJEEBHOY TOWERS,
DALAL STREET,
MUMBAI – 400 001.

BSE CODE – 524348

TO,
THE SECRETARY
THE NATIONAL STOCK EXCHANGE OF INDIA LTD.,
EXCHANGE PLAZA, 5TH FLOOR,
PLOT NO.C/1,G BLOCK,
BANDRA-KURLA COMPLEX,
BANDRA (E), MUMBAI – 400 051.

NSE CODE: AARTIDRUGS

Dear Sir/Madam,

Ref : Compliance of Clause 41 of the Listing Agreement.
Sub: Merged Audited Financial Results for the year ended 31st March, 2012.

In terms of Clause 41 of the Listing Agreement, we are forwarding herewith the merged Audited Financial Results along with the Auditor's Report on Annual Financial Results of the Company for the year ended 31st March, 2012 in the prescribed form which have been taken on record by the Board of Directors of the Company at its meeting held on Monday, 9th July, 2012 at Mumbai.

Further, please note that the Company has already made necessary arrangement to publish the same in the newspapers as required under the Listing Agreement.

Please take note of the same on your record.

Thanking you,

Yours faithfully,
For **AARTI DRUGS LIMITED**

SUNNY PAGARE
COMPANY SECRETARY
Encl: as above.

Regd. Office : Plot No. N-198, MIDC, Tarapur, Tal-Palghar, Dist. Thane - 401 506. (MH)

Notes :

1 The above Regd results for the year ended 31st March, 2012 have been reviewed by the Audit Committee and approved by the Board of Directors in their meeting held on 9th July, 2012 consequent upon amalgamation of Sylvan Laboratories Limited (Transferor Company) (being wholly owned subsidiary of Aarti Drugs Limited) with Aarti Drugs Limited(Transferee Company) having become operative from 01.04.2011 (Appointed Date).

2 The Board of Directors has already recommended a Final Dividend of Rs. 3.00/- per Equity Share for the year 2011-12 to the members of the Company.

3 Company is operating as a Single Segment Company, engaged in Pharmaceuticals Business.

4 Figures for the previous period have been regrouped or rearranged wherever necessary.

5 Previous years's figures are of Aarti Drugs Limited stand alone and hence are not comparable.

For and on behalf of the Board
For AARTI DRUGS LIMITED

HARSHIT M. SAVLA
(JT. MANAGING DIRECTOR)

Place : Mumbai
Date: 9th July, 2012

STATEMENT OF ASSETS AND LIABILITIES AS AT 31ST MARCH, 2012

(Rs. in Lacs)

Particulars	For the year ended 31/03/2012	For the year ended 31/03/2011
A EQUITY AND LIABILITIES		
1 Shareholder' funds		
(a) Share Capital	1,211	1,211
(b) Reserves and surplus	16,437	14,441
2 Non-current liabilities		
(a) Long - term borrowings	6,692	7,434
(b) Deferred tax liabilities (net)	771	757
(c) Other long - term liabilities	447	2,230
(d) Long - term provisions	-	-
Sub - total - Non - current liabilities	8,911	10,421
3 Current liabilities		
(a) Short - term borrowings	20,557	14,725
(b) Trade payables	3,379	7,736
(c) Other current liabilities	2,866	2,416
(d) Short - term provisions	902	641
Sub - total - current liabilities	33,703	25,517
TOTAL - EQUITY AND LIABILITIES	61,262	51,589
B ASSETS		
1 Non-current assets		
(a) Fixed assets	27,653	23,458
(b) Non - current investments	692	2,461
(c) Long - term loans and advances	227	863
Sub - total - Non - current assets	28,572	26,782
2 Current assets		
(a) Inventories	9,791	8,316
(b) Trade receivables	18,060	12,589
(c) Cash and cash equivalents	2,715	2,276
(d) Short - term loans and advances	494	359
(e) Other non - current assets	1,630	1,279
Sub - total - current assets	32,691	24,807
TOTAL - ASSETS	61,262	51,589

Manufacturers of : Bulk Drugs & Chemicals Website : www.aartidrugs.com

Aarti Drugs Limited

Manufacturers of : Bulk Drugs & Chemicals

Corporate Office : Mahendra Industrial Estate, Ground Floor, Plot No. 109-D, Road No. 29, Sion (East), Mumbai - 400 022. (India)
Tel.: 022-2407 2249 / 2401 9025 (30 Lines)
Fax : 022-2407 3462 / 2407 0144
Email : finacc@aartidrugs.com
Website : www.aartidrugs.com

AARTI DRUGS LIMITED

PART I

STATEMENT OF AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31ST MARCH, 2012

Sr. No.	Particulars	Quarter Ended			Financial Year Ended	
		31st Mar 2012 (Audited)	31st Dec 2011 (Audited)	31st Mar 11 (Audited)	31st Mar 2012 (Audited)	31st Mar 2011 (Audited)
1	**Income from Operations**					
	(a) Gross Sales / Income from Operations	21,165	16,394	15,102	**69,918**	52,301
	Less : Excise Duty & Sales Tax	1,242	885	767	**3,992**	2,659
	(a) Net Sales / Income from Operations (Net Of Excise Duty & Sales Tax)	**19,923**	15,509	14,335	**65,926**	49,642
	(b) Other Operating Income	**590**	3	1	**610**	8
	Total income form operations (net)	**20,513**	15,512	14,336	**66,536**	49,650
2	**Expenditure**					
	(a).Cost of materials consumed	**9,960**	8,660	7,985	**38,414**	27,300
	(b) Purchase of stock-in-trade	**2,480**	1,669	1,849	**7,336**	8,421
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	**1,884**	353	352	**(82)**	(1,618)
	(d). Employee benefits expense	**762**	523	476	**2,483**	1,787
	(e). Depreciation and amortisation expense	**629**	498	474	**2,422**	1,774
	(f). Other expenses	**2,789**	2,591	2,057	**10,368**	7,490
	Total expenses	**18,504**	14,264	13,193	**80,931**	45,155
3	**Profit from Operations before Other Income, finance costs and exceptional items (1-2)**	**2,009**	1,248	1,143	**5,605**	4,495
4	Other Income	-	-	-	-	-
5	**Profit from ordinary activities before finance cost and exceptional items (3+4)**	2,009	1,248	1,143	5,605	4,495
6	Finance costs (interest)	**697**	574	409	**2,267**	1,348
7	**Profit from ordinary activities after finance cost but before Exceptional Items (5±6)**	1,312	674	734	3,338	3,147
8	Exceptional Items	116	-	-	116	-
9	**Profit from Ordinary Activities before Tax (7±8)**	1,196	674	734	3,222	3,147
10	**Tax Expenses (Includes)**	**454**	193	105	**976**	900
	Provision for Taxation	390	119	64	800	650
	Provision for Deferred Taxation	64	74	41	176	250
11	**Net profit from ordinary Activities after Tax**	741	481	629	**2,246**	2,247
13	Paid-up Equity Share Capital of ₹10/- each.	1,211	1,211	1,211	**1,211**	1,211
14	Reserves & Surplus (excluding revaluation reserves)	-	-	-	**16,437**	14,441
15.	**Earning per share (of Rs/- each) (not annualised)**					
	(a) Basic & Diluted	6.11	3.97	5.19	**17.84**	18.56

PART II (₹ in Lakhs)

A	**PARTICULARS OF SHAREHOLDING**					
1	Public shareholding					
	-Number of Shares	**5,379,245**	5,469,611	5,569,613	**5,379,245**	5,569,613
	-Percentage of Total Shareholding	**44.43**	45.17	46.00	**44.43**	46.00
2	**Promoters & Promoter Group shareholding**					
	a) Pledged/Encumbered					
	- Number of Shares	Nil	Nil	Nil	Nil	Nil
	-Percentage of shares(as a % of the total shareholding of promoter and promoter group)	Nil	Nil	Nil	Nil	Nil
	-Percentage of shares(as a % of the total Share capital of the company)	Nil	Nil	Nil	Nil	Nil
	b) Non-encumbered					
	- Number of Shares	**6,729,305**	6,638,739	6,538,937	**6,729,305**	6,538,937
	-Percentage of shares(as a % of the total Shareholding of promoter and promoter group)	**100**	100	100	**100**	100
	-Percentage of shares(as a % of the total Share capital of the company)	**55.57**	54.83	54.00	**55.57**	54.00

B	**INVESTOR COMPLAINTS**	Qtr ended 31st March, 2012
	Pending at the beginning of the quarter	0
	Received during the quarter	3
	Disposed of during the quarter	3
	Remaining unresolved at the end of the quarter	0

Regd. Office : Plot No. N-198, MIDC, Tarapur, Tal-Palghar, Dist. Thane - 401 506. (MH)

PARIKH JOSHI & KOTHARE (Regd.)

CHARTERED ACCOUNTANTS

49/2341, M. H. B. Colony,
Gandhi Nagar, Bandra (East),
Mumbai 400 051.

Tele: 2645 1439/2651 5396
Fax : 91-22-2645 5867
Email: pjk@mtnl.net.in

Auditor's Report On Quarterly and Annual Financial Results of Aarti Drugs Ltd Pursuant to the Clause 41 of the Listing Agreement

To
Board of Directors of Aarti Drugs Ltd

We have audited the quarterly financial results of Aarti Drugs Ltd ('the company'), post amalgamation of Suyash Laboratories Ltd with the Company, for the quarter ended 31st March, 2012 and the annual results for the period 1st April, 2011 to 31st March, 2012 attached herewith, being submitted by the company pursuant to the requirement of clause 41 of the Listing Agreement except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been audited by us. These quarterly financial results have been prepared on the basis of the interim financial statements and annual financial results have been prepared on the basis of the annual financial statements, which are the responsibility of the company's management. Our responsibility is to express an opinion on these financial results based on our audit of such interim financial statements, which have been prepared in accordance with the recognition and measurement principles laid down in Accounting Standard (AS) 25, Interim Financial Reporting, issued pursuant to the Companies (Accounting Standards) Rules, 2006 as per section 211(3C) of the Companies Act, 1956 and other accounting principles generally accepted in India and the annual financial statements audited by us.

We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatements. An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by management. We believe that our audit provides a reasonable basis for our opinion. The report of Suyash Laboratories Ltd, audited by other auditors has been forwarded to us and has been dealt with by us in preparing this report.

In our opinion and to the best of our information and according to the explanations given to us these quarterly financial results as well as the annual results:

(i) are presented in accordance with the requirements of clause 41 of the Listing Agreement in this regard; and

(ii) give a true and fair view of the net profit and other financial information for the quarter ended 31st March, 2012 as well as the annual results for the period from 1st April, 2011 to 31st March, 2012.

Further, we also report that we have, on the basis of the books of account and other records and information and explanations given to us by the management, verified the number of shares as well as percentage of shareholdings in respect of aggregate amount of non promoter shareholdings, as furnished by the company in terms of clause 35 of the Listing Agreement and found the same to be correct.

For PARIKH JOSHI & KOTHARE
CHARTERED ACCOUNTANTS



YATIN R. VYAVAHARKAR
PARTNER
M.No. 33915
Firm Registration No.: 107547W

Mumbai,
Dated: July 9, 2012